Novartis
Novartis has 5 source-linked AI deployments documented in AIUseCaseHub, across 2 industries and 3 countries.
Hyperscaler mix
See whether Novartis's cases are powered by Microsoft, AWS, GCP, or multiple providers.
How Novartis builds AI
Build / Buy / Compose across this company's documented cases
5 of 5 cases classified (100%) · Compare all use-case types
Reported outcomes
1 case reports measurable results
−75%
Time & speed
median · 2 metrics
Medians of results published in Novartis cases, normalized for comparability. See all benchmarks →
Evidence persistence
5 of 5 judgeable cases are still publicly referenced · 5 show the organization expanding AI use.
Durability of public evidence, not whether systems remain in production. How this is measured →
Technology snapshot
What Novartis uses across visible cases
Capability flags and technologies mentioned in the indexed use cases on this page.
- Top use case
- Vision
- Tagged cases
- 3/5
- Tech names
- 7
Capability mix
Technologies mentioned
All Use Cases (5)
AstraZeneca and Novartis Scale AI Across Pharma Value Chain
This article provides a comprehensive overview of how leading pharmaceutical firms—including AstraZeneca, Novartis, Sanofi, GSK, Genentech, and AbbVie—are integrating Microsoft technologies such as Azure AI, Machine Learning, Cognitive Services, and Power Platform to transform drug development and operations. Real-world examples cover AI-powered drug target identification, generative molecule design, clinical trial acceleration, pharmacovigilance, supply chain optimization, and patient engagement via chatbots. The piece details both the tangible business benefits (shortened timelines, reduced costs, improved trial precision, and better patient outcomes) and persistent challenges such as data fragmentation, legacy systems, regulatory complexities, and change management. Strategic priorities for CIOs and IT leaders on how to industrialize AI, ensure enterprise-wide adoption, and promote responsible, cross-functional scaling of Microsoft technologies are emphasized. The article highlights collaborations like AstraZeneca’s enterprise AI roadmap, Novartis-Microsoft innovation lab, and Sanofi’s infrastructure modernization to demonstrate mature, scalable uses of cloud-based AI.Challenges with data interoperability, legacy infrastructure, talent and cultural adoption, and regulatory risk are addressed alongside solutions such as human-in-the-loop designs, explainable AI, and real-time learning cycles aligned with scientific and compliance goals.
Novartis revolutionizes drug discovery with Microsoft Azure AI
Novartis has partnered with Microsoft to enhance its drug discovery processes by leveraging AI technologies provided by Azure. This collaboration enables Novartis scientists to ana...
Microsoft
Novartis Develops Advanced Medicines Using AI
Novartis partnered with Microsoft to integrate Microsoft's AI-powered solutions directly into their drug research processes in Basel, Switzerland. This collaboration enabled machin...
Microsoft
Novartis redefines pharma R&D with global AI-driven workflows
Novartis initiated a five-year collaboration with Microsoft to accelerate drug discovery, enhance clinical trials, and streamline manufacturing processes using AI and machine learning. The establishment of an AI Innovation Lab across international locations aims to integrate AI tools into daily workflows for all employees.The partnership includes joint research projects focusing on personalized treatments for eye diseases, next-generation manufacturing for advanced therapies, and rapid design of new drug molecules.AI and data science techniques such as image segmentation and analysis are leveraged for personalized medicine development and efficiency improvements.Data-driven insights are delivered directly to associates—enabling 'citizen data scientists' without deep technical expertise to access and utilize AI-powered analytics in decision-making.Projects include remote digital clinical trials and digital therapeutics, emphasizing accessibility for underserved populations, and the data42 platform mining company data for key patterns.Co-working centers in Switzerland, Ireland, and the UK serve as hubs for scalable AI experimentation and innovation.The collaboration seeks to address key pharmaceutical industry challenges, lower patient costs, and reimagine data-driven R&D processes.Both companies share expertise: Novartis with biology and medicine, Microsoft with cloud/data/AI technologies.The project has led to greater workflow efficiency, faster therapeutic discovery, and empowered a data-first organizational shift at Novartis.Microsoft’s AI tools further enhance access to the company’s large clinical/scientific datasets, providing an accessible interface for non-data scientists.
Novartis and Microsoft revolutionize healthcare with AI-driven collaboration
Novartis collaborates with Microsoft to leverage AI for enhancing drug discovery and improving healthcare delivery. This partnership includes deploying AI-enabled digital health to...